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(Abstract: 225/250 words including headers) 
 
Objective: To develop and scale algorithm-enabled patient prioritization to improve population-
level management of type 1 diabetes (T1D) in a pediatric clinic with fixed resources, using 
telemedicine and remote monitoring of patients via continuous glucose monitor (CGM) data 
review.  
 
Research Design and Methods: We adapted consensus glucose targets for T1D patients 
using CGM to identify interpretable clinical criteria to prioritize patients for weekly provider 
review. The criteria were constructed to manage the number of patients reviewed weekly and 
identify patients who most needed provider contact. We developed an interactive dashboard to 
display CGM data relevant for the patients prioritized for review. 
 
Results: The introduction of the new criteria and interactive dashboard was associated with a 
60% reduction in the mean time spent by diabetes team members who remotely and 
asynchronously reviewed patient data and contacted patients, from 3.2±0.20 to 1.3±0.24 
minutes per patient per week. Given fixed resources for review, this corresponded to an 
estimated 147% increase in weekly clinic capacity. Patients who qualified for and received 
remote review (n=58) have associated 8.8 percentage points (pp) (95% CI = 0.6–16.9pp) 
greater time-in-range (70-180 mg/dL) glucoses compared to 25 control patients who did not 
qualify at twelve months after T1D onset. 
 
Conclusions: An algorithm-enabled prioritization of T1D patients with CGM for asynchronous 
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Continuous glucose monitoring (CGM) and data-driven care tools improve patient outcomes.1–3  
CGM use is recommended for all patients with T1D and augments the capabilities of 
telemedicine in diabetes care.4 Unfortunately, a majority of patients with T1D still self-monitor 
their blood glucose through finger-sticks. A majority also fail to meet HbA1c targets.5 Gaps in 
diabetes technology use and patient outcomes are further exacerbated by structural racial and 
socioeconomic disparities.6,7 
 
Clinics seeking to expand access to their telemedicine program, especially to underserved 
populations geographically separated from pediatric endocrinologists, stand to benefit from 
efficiencies that allow them to serve more patients with their current resources. CGM-enabled 
telemedicine (synchronous and asynchronous) could expand specialized T1D care to 
underserved areas through comprehensive care networks.8,9 The automation of time-consuming 
tasks that do not require human expertise can free provider time, thus enabling clinics to care 
for more patients while improving patient outcomes, without requiring additional resources. 
Clinic efficiency may improve with algorithms that help providers accurately identify patients with 
suboptimal glucose control without having to manually review data for the whole clinic 
population.  
 
In order to facilitate efficient care delivery for patients using CGM, clinics need help analyzing 
large amounts of CGM data and limiting the total review time required of providers.10 Data 
science and algorithm design have the potential to direct attention to the patients most likely to 
benefit from provider contact and to fill existing technical deficiencies to enable the Digital 
Diabetes Clinic.11,12 Many tools exist to analyze CGM data for an individual patient.13–15 But, to 
our knowledge, no open-source, CGM manufacturer-independent tools are available to help 
clinics analyze CGM data and manage their entire T1D clinic population.  
 
In a clinic providing T1D care through synchronous and asynchronous telemedicine based on 
the review of CGM data, we demonstrate an approach to reduce provider review time per 
patient by prioritizing patients based on their likelihood of benefiting from an intervention by the 
care team. We do so by evaluating the impact of an interactive patient CGM glucose data 
dashboard that makes it possible to expand periodic asynchronous remote CGM review to 
larger patient populations without increasing provider screen time or negatively affecting 
patients' glucose control.  We developed an algorithm that ranks patients by their number of 
flags (i.e., indicators of glucose outside of targets), and then by ascending time in range (TIR).  
Based on earlier work providing population-level care through the analysis of CGM data, we 
hypothesized such an algorithm would yield both high sensitivity and high specificity.1 The 
algorithm is based on consensus guidelines, is available through free open-source software, is 
compatible with data from any manufacturer that support raw data extracts, and allows clinics to 
specify their own patient review criteria based on their capacity constraints.16,17 After deploying 
the algorithm to identify patients for remote review, we estimated the effect of remote review on 
provider time and CGM TIR by comparing patients who did and did not receive remote review. 
We hypothesized that: 1) clinic patient capacity would increase as a result of changes in time 
spent on review and patient contacts, and that 2) remote review and individual contacts would 
improve patient’s CGM glucose TIR.   
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This study consisted of two stages: a retrospective cohort review as part of a non-randomized 
quality improvement effort in an academic, pediatric T1D clinic; this was followed by a 
prospective case-control evaluation of the clinical workflow and patient glucose management. 
The Stanford University Institutional Review Board approved this work. Patients and families 
gave informed consent (or assent) prior to participating.  
 
Settings and participants 
 
The work was conducted at a pediatric T1D clinic at a large pediatric academic medical center. 
Participants included all new T1D patients that chose to enroll in the remote review program. 
Participants in this program were provided with 1 month of CGM supplies and insurance 
approval was obtained for ongoing coverage as part of a research protocol. Participants who did 
not have their own iOS devices were provided with an iPod Touch to facilitate data sharing. 
Since this analysis is part of an ongoing pilot study, additional participants were added weekly.18 
 
Before the work described here, the clinic was performing manual weekly CGM review of 
patients enrolled in the study.1 Our study and datasets are split into four periods: Period 0 is the 
historical period used to simulate, evaluate and define new review criteria; Period 1 immediately 
precedes the introduction of our new review criteria and serves as the baseline we use to 
measure the effects of our changes; Period 2 begins after our new review criteria are deployed 
in the clinic; and Period 3 is the measurement period after we deploy an interactive dashboard 
to simplify the review workflow. 
 
Clinical metrics, targets, and the patient priority ranking  
 
The new criteria to prioritize patients for data review and a potential telehealth visit were 
generated based on a modified version of consensus guideline targets.15,17 Standard CGM 
metrics were used in this study: percent-worn (PW) is the proportion of time with recorded 
glucose readings, time-in-range (TIR) is defined as glucose readings 70-180 mg/dL, clinically 
significant hypoglycemia (csHyp) is defined as glucose readings below 54 mg/dL, and 
hypoglycemic (Hyp) is defined as the glucose readings below 70 mg/dL. A patient must have a 
PW ≥ 75% to be eligible for remote review during each study week. For the eligible patients, we 
defined three potential “flags” that could be raised for each patient each week: (1) TIR < 65%, 
(2) csHyp > 1%, and (3) Hyp > 4%. Patients with insufficient readings were contacted to 
understand the reason for missing measurements (e.g. out of supplies, technical issues, taking 
CGM break). 
 
Patients were ranked (i.e., prioritized for review) in descending order of number of flags.  Within 
groups of patients that have the same number of flags, patients were ranked in ascending order 
of TIR. This combined ranking is what we subsequently deployed in our dashboard in Period 2 
All rights reserved. No reuse allowed without permission. 
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 





to replace the existing review criteria in Period 1, which involved reviewing all patients with TIR 
< 70%, csHyp > 1%, or Hyp > 4%. 
 
Creation and evaluation of criteria for review based on retrospective data 
 
In the first stage of the study, we developed criteria for review using a historical dataset from 
patients in our clinic. During this historical period, the data of patients with and without any of 
the flags described above were reviewed remotely by a Certified Diabetes Educator (CDE). The 
historical dataset included weekly data on which patients had their CGM data reviewed by a 
CDE and which patients had been contacted as a result of this review. We estimated the priority 
rank of each patient in each of the previous weeks they had passively uploaded CGM data. 
 
CDEs were presented with a choice for how many patients to review weekly, K, (ordered by our 
ranking function) and the sensitivity and specificity corresponding to each choice. We generated 
a receiver operating characteristic (ROC) curve that graphs the positive predictive value (PPV; 
precision) and sensitivity for each possible value of K. PPV is defined as the proportion of 
patients meeting the review criteria that were contacted in the historical data. Sensitivity is 
defined as the proportion of patients contacted historically that met the evaluated review criteria.  
 
As K increases, more patients are reviewed and the CDEs are more likely to review all the 
patients they would contact if they reviewed them. But there is also a cost associated with 
increasing K: CDE resources are limited, and so there is a limit to the clinic population they can 
monitor. Small values of K correspond to the potential for more patients to be monitored given a 
fixed amount of CDE time.  
 
We simulated an additional option to review all patients who had flags over the past two 
consecutive weeks along with the top K patients according to the ranking function, in order to 
ensure that patients with flags in two consecutive weeks were reviewed despite ranking below 
the top K.  
 
The hypothetical number of patients reviewed weekly along with sensitivity estimates of each 
candidate criteria were presented to the clinical staff along with a comparison against the 
existing review criteria in Period 1. The new criteria they chose was implemented in a 
dashboard used by the clinic to prioritize which patients to review each week  
 
Deployment in an academic, pediatric T1D clinic 
 
The new review criteria were first deployed in Period 2 in the R Shiny dashboard the clinic was 
already using during Period 1 to determine which patients’ CGM data the CDEs should review 
each week (Figure 1). The change did not require modifying the existing workflow of the CDEs. 
The system that delivers patient CGM data to the clinic via Dexcom Clarity, as well as the 
clinic’s R Shiny dashboard, is described in Scheinker et al.1 
 
The criteria were later deployed in an interactive Tableau dashboard in Period 3 (Figures 2 and 
3). Unlike the R Shiny dashboard, the Tableau dashboard also showed each patient’s glucose 
data, including the Ambulatory Glucose Profile (AGP) view that quickly summarizes their data.19 
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Showing these data was intended to eliminate the need for the CDEs to log into a separate web 
portal (Dexcom Clarity) to review patients’ data and to reduce the time needed to review each 
patient. 
 
The time spent on reviewing patients’ CGM data and on contacting patients was tracked by the 
CDE performing the data review. The steps involved in this process were identifying a patient 
with a flag, opening Dexcom Clarity (for the R Shiny tool, but not the Tableau tool), reviewing 
the patient’s data; then if the CDE believed the patient needed a contact, they would open up 
the EHR, send a secure message, and potentially update insulin dosages in the chart. 
 
After the new criteria took effect in Period 2, we continued recording the number of patients 
eligible for review each week, the number flagged for review, and the number contacted each 
week. Before and after the interactive dashboard was deployed in Period 3, CDEs reported the 
average time they spent reviewing a patient’s CGM data and the average time they spent 
contacting each patient after data review (sending messages and updating charts). We 
estimated the total time spent on review and contacts each week by multiplying the times 




The primary outcome for this study was the change to clinic patient capacity as a result of 
changes in time spent on review and patient contacts. This operational metric was estimated as 
the total amount of CDE time available weekly divided by the time necessary to review CGM 
data and make contacts per patient eligible for remote review in a given week. 
 
A secondary outcome was the effect of remote review and individual contacts on glucose 
management. This was measured in three ways: (1) the weekly TIR at twelve months since first 
diagnosis of diabetes compared to a control cohort in the same clinic, (2) the difference in 
weekly TIR between patients with and without contacts in the preceding week, controlling for the 
TIR in the week preceding contact, and (3) the difference in the odds that a patient’s TIR 
improved by 5pp or more between patients with and without contacts in the preceding week, 
controlling for the TIR in the week preceding contact. 
 
Estimating the effect of remote review and contacts on glucose management 
 
We compared the mean TIR in each month since diabetes onset among the clinic cohort with 
remote review to a cohort in the same clinic without remote review. Patients were included if 
they started CGM within a month after diagnosis, submitted CGM measurements a year after 
diagnosis, and had consented to the relevant IRB protocol. The primary reason some patients 
were ineligible for remote review was that their diabetes diagnoses happened before the clinic 
had received IRB approval for remote monitoring. 
 
We performed regression modeling of the TIR during a patient-week to estimate the mean 
difference in TIR associated with a remote contact in the previous week while controlling for the 
patient’s TIR two weeks earlier. We fit two linear regression models: one with patient-level 
random effects and one with patient-level fixed effects. Beyond the ranking, CDEs’ choices of 
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which patients to contact depends on the patients’ state; to further control for this effect, we fit a 
propensity model of contact and estimated the effects of contacts using a causal forest model 
(Supplement).20  
 
We performed logistic regression modeling of the binary outcome that the change in TIR for a 
patient is 5pp or greater between the week preceding a potential contact and the week following 
a potential contact, estimating the relative odds ratio of a ≥5pp change when there was a 
contact in the middle week relative to when there was no contact, controlling for the TIR of the 





Analysis of historical data and definition of new review criteria 
 
The population analyzed grew from 53 patients in Period 0 (historical data used to define new 
review criteria) to 225 patients in Period 3 (after deployment of the interactive dashboard for 
patient review). Cohort characteristics across periods are summarized in Table 1.  
 
When using the criteria from Period 1, which mandated a manual review for each patient with a 
flag, CDEs reviewed data from 26 patients weekly on average. This number decreased to an 
estimated 22 patients with the new criteria: 20 patients selected by the ranking function and 2 
patients with flags over the past two consecutive weeks (Figure 4).  
 
Deployment in an academic, pediatric T1D clinic 
 
After adopting the new criteria described above within the clinic’s R Shiny dashboard in Period 2 
(Figure 1), the number of patients flagged each week dropped to 26 the following week. In the 
following months, the number of patients eligible for review increased slightly but the number of 
patients contacted remained stable (Figure 5). 
 
Using the per-patient CDE-reported time estimates for CGM data review (2 minutes per patient 
reviewed), and EMR-based updates and messaging (3 minutes per patient contacted) with our 
tool, we estimated the time spent reviewing and messaging patients each week before and after 
the criteria change. The estimated time spent per patient eligible for review in the population 
dropped 36% from 3.2±0.20 to 2.0±0.21 minutes in the three weeks after the criteria change as 
compared to the three weeks before the change (Figure 5). This time reduction resulted from 
the lower number of weekly patient reviews with the revised criteria (Figure 5).  
 
With an estimated fixed weekly 209 minutes available for reviewing CGM data and contacting 
patients, the measured 36% reduction in time spent per patient corresponds to a 56% increase 
in the estimated maximum clinic patient capacity (from 66 to 103 patients; Figure 2). 
 
In November 2020, we deployed an interactive Tableau dashboard (Figures 2 and 3) to replace 
the clinic’s R Shiny dashboard (Figure 1).  Based on self-reported time measurements from the 
clinic’s CDEs, the new dashboard reduced the mean time CDEs spent reviewing each indicated 
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patient’s CGM data from 2 minutes to 1 minute. CDEs could review each patient’s CGM data on 
a single platform, rather than the previously required access to a separate webpage for each 
patient. As a result, the estimated time spent per patient in the population dropped 37% from 2.0 
to 1.3 minutes and the estimated clinic patient capacity increased by an additional 58%. 
 
When combined, these two changes reduced the estimated per patient time spent on review 
and contact by 60%, from 3.2±0.20 to 1.3±0.24 minutes and increased the estimated clinic 
capacity by 147% (97 patients). 
 
Estimating the effect of remote review and contacts on glucose management 
 
The mean TIR at 12 months since diagnosis was 65.8% for patients eligible for remote review 
and 57.0% for those who were enrolled in the study prior to remote review being established, 
which represents an improvement of 8.8pp (CI = 0.6–16.9pp) (Figure 6) 
 
Contact with a care provider was associated with an increase in the TIR the following week of 
1.6pp (P = 0.02) in a model with patient random effects and an increase of 2.3pp (P < 0.001) in 
a model with patient fixed effects. These effect estimates were consistent with the results of a 
causal forest model (details in Supplement). 
 
Contact with a care provider was associated with a greater chance of a TIR improvement of 5pp 
or more, with an odds ratio (OR) of 1.29 (CI = 1.02–1.64; P = 0.03) in a model with patient 
random effects and OR of 1.34 (CI = 1.05–1.71; P = 0.02) in a model with patient fixed effects 





In a pediatric T1D clinic at an academic medical center, the use of an algorithmic approach to 
identifying patients most likely to benefit from an asynchronous telemedicine contact was 
associated with a 60% reduction in the per-patient time required for review and contact and 29-
34% increased odds of improving time-in-range by 5pp during the week following contact. The 
algorithm was based on clinician-developed review criteria. Its use decreased the proportion of 
patients in a clinic receiving remote provider CGM review each week without reducing the 
number of clinically indicated patient contacts. The improved efficiency corresponded to an 
estimated 147% increase in clinic capacity, from 66 patients to 163 patients, without requiring 
additional resources, and while improving patient glucose control. 
 
Algorithm-enabled patient prioritization safely frees up provider time relative to reviewing all 
patients using CGM, which is not currently done due to it not being feasible. Consider a patient 
with TIR just below the consensus target one week and above target in the following week. The 
patient would not be reviewed if there are many other patients further outside of glucose targets 
or experiencing poor glucose control over longer time periods. These improvements enable an 
expansion of the patient population eligible for remote CGM review.  Further, our results 
suggest a strong association between remote review and contact, and subsequent improvement 
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in patient glucose control. Use of this algorithm facilitates a precision medicine approach 
translated to a clinic population in which patients receive clinician attention based on CGM data. 
 
The tool described has been made available as open-source software.21 Our team will provide 
clinical and operational support for adoption by other clinics. The guideline-based inputs to the 
ranking function are fully interpretable and in-line with the latest consensus guidelines. Clinics 
already monitoring patients using CGMs may calibrate the tool to fit their preferred 
sensitivity/specificity trade-off. A clinic without a remote monitoring program may use the default 
settings of the tool. Earlier work in the development of this tool suggests that the types of alerts 
used may be calibrated based on the glucose management of the population cared for by the 
clinic.1 
 
For identifying patients that had previously been contacted by CDEs after they reviewed the 
patients’ CGM data, in our clinic we found that a target of 65% TIR optimized specificity.1 This 
decision was supported by our clinical collaborators as an acceptable way to more efficiently 
target patients in need of intervention. Our target use of a 65% TIR target in the algorithm, 
which differs from the consensus guideline 70% TIR target, is one example of how the algorithm 
may be tailored to specific clinic populations and practices. Future directions include adjustment 
of this target to improve TIR and maintain efficiency. 
 
We employed widely used tools (Python, Dexcom Clarity, R and Tableau) to produce these 
results. To our knowledge, existing CGM review tools either focus only on individual patients, 
are not open source, and/or show clinic population statistics only for patients wearing the same 
type of sensor.22 Our tool is open source and can work with CGM data from any source that 
supports raw data exports. These algorithms require minimal input and can be run on an 
ordinary laptop. Barriers to the implementation at scale of algorithm-enabled improvements to 
T1D care will more likely be associated with ancillary difficulties (secure data access, data 
provision by device manufacturers, and agreement with local regulations), than with the 
technical challenges of using it. Policymakers, patients, physicians, and other stakeholders 
should engage with the issue of data sharing to ensure that the failures that plague EMR 
interoperability and data sharing do not befall CGM data.23 In the US, the 21st Century Cures Act 
provides a framework to facilitate patient, family, and provider access to medical records and 
electronic health information.24 
 
Our work facilitates the expansion of remote CGM review to larger patient populations and 
potentially to smaller primary care clinics. While increases in clinic capacity present an 
opportunity to expand access among disadvantaged populations, a thoughtful implementation is 
paramount to avoid the risk of intervention-generated inequalities.25 The ADA recommends 
CGM for all youth with T1D, but currently access to CGM is limited for youth on public 
insurance, increasing disparities.  Access to CGM is a first step, and needs to be combined with 
diabetes education, as well as collaboration with the diabetes care team to assist with insulin 
dose adjustments as needed to achieve tight glucose control. Numerous steps are necessary to 
ensure that underserved populations reap the benefits associated with care enabled by new 
technologies.7,26 
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Further research is required to evaluate how our methods can be best applied in a clinic with 
multiple providers reviewing CGM data. A clinic-level prioritization tool may generate additional 
benefits when multiple providers are involved with patient care, rather than a split cohort setting 
like ours. Such a tool may also support and standardize the training and integration of new 
providers. Including insulin data in the tools used by CDEs could help inform treatment 
decisions. Better understanding of how individual patients respond to remote contacts and 
adding personalized CGM targets for patients may unlock further efficiencies in how provider 
resources are allocated within the clinic. 
 
The limitations of our work include a small sample population size of mostly new onset patients, 
reducing our ability to detect small changes in patients’ glucose measurements or HbA1c that 
resulted from our work. Further, time allocation and capacity calculations were based on 
estimates from experienced CDEs. Prospectively collected objective measurements of time 
allocation would strengthen future studies. Note that our results on increased clinic capacity are 
fairly robust to even large errors in the CDE time estimates per patient, as they rely primarily on 
safe decreases in the number of patients requiring review each week and secondarily on 
marginal time savings associated with a simpler review workflow. Our estimation of the effect of 
provider contacts is limited by remote review not being randomly assigned to patients, which 
limits our ability to make causal claims. We also cannot conclude how our work would translate 
to primary care, adult T1D, or type 2 diabetes clinics. 
 
In conclusion, an algorithm-enabled prioritization of T1D patients with CGM for asynchronous 
remote review reduced provider time spent per patient by over 60% and was associated with 
improved TIR. This demonstrates that a pediatric T1D clinic with fixed resources may be able to 
increase its capacity and TIR through standardized, population-level, algorithm-enabled CGM 
data review and telemedicine. Algorithmic improvements to clinic capacity may present an 
opportunity to expand access to remote CGM review, especially to underserved populations 
without local access to pediatric endocrinologists.  
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TABLES AND FIGURES: 
 










Female, No (%) 18 (34.0%) 49 (47.1%) 92 (45.8%) 110 (48.9%) 
Public Insurance, No (%) 9 (17.0%) 21 (20.2%) 73 (36.3%) 86 (38.2%) 
Age on May 25, 2020, median [IQR] 11.0 [7.0, 14.0] 10.0 [7.0, 14.0] 11.0 [7.0, 14.0] 11.0 [8.0, 14.0] 
CGM recordings, mean No per patient 
(SD) 14500 (4780) 9160 (2920) 29600 (16900) 15400 (7580) 
CGM days, mean No per patient (SD) 54.5 (15.2) 34.3 (9.17) 114 (59.0) 58.1 (25.7) 
CGM weeks, mean No per patient (SD) 9.09 (1.92) 6.45 (1.28) 18.1 (8.28) 8.94 (3.27) 
Mean glucose, mean (SD) 166 (30.1) 158 (31.7) 167 (38.3) 172 (42.9) 
Prop. of time in range†, mean percent 
(SD) 63.3 (18.7) 67.0 (19.0) 62.2 (21.3) 60.2 (23.3) 
Prop. of time hypoglycemic‡, mean 
percent (SD) 1.98 (2.15) 2.21 (2.31) 2.28 (3.01) 2.07 (2.49) 
Prop. of time with clinically significant 
hypoglycemia§, mean percent (SD) 0.311 (0.631) 0.339 (0.538) 0.418 (1.14) 0.343 (0.667) 
Data from Period 0 (2020-01-24 to 2020-03-26) was used to define the new criteria for remote review. 
Period 1 (2020-03-27 to 2020-05-04) defined the baseline number of reviews and contacts before the new criteria 
were implemented. 
Period 2 (2020-05-25 to 2020-11-09) was used to evaluate the performance of the new criteria. 
Period 3 (2020-11-16 to 2021-01-31) provided data to evaluate the changes in metrics after the interactive Tableau 
dashboard was deployed. 
Many of the same patients are included in the data from each period. 
† readings 70-180 mg/dL. 
‡ readings < 70 mg/dL. 
§ readings < 54 mg/dL. 
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Figure 1: R Shiny Dashboard 
Patients are ranked according to our new criteria. Individual patient’s data has to be reviewed separately in a web browser. The later interactive dashboard 
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Figure 2: Interactive Tableau Dashboard (Population View) 
 
Patients are ranked according to our new clinical criteria. Once a CDE clicks on a patient, metrics and graphs below the table update to show a summary of that 
patient’s CGM data (see Figure 6).  
A
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Figure 3: Interactive Tableau Dashboard (Patient View) 
  
This view updates to show data for the patient selected in the population view (Figure 2). 
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Figure 4: Receiver Operating Characteristic Curve Showing the Estimated Improvement 
in Positive Predictive Value from a Change in Review Criteria, Based on Historical Data 
Our change moved our historical performance from the red point (previous criteria) to the green point (new criteria), 
increasing the historical positive predictive value from 0.65 to 0.76 while only reducing historical sensitivity from 0.91 
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Figure 5: Time Saved, Increase in Clinic Capacity and Patients Eligible after Tool 
Changes 
In both panels: the first vertical dashed line from the left shows the time of the review criteria change. The second line 
shows the time of the Tableau tool deployment. In the bottom panel: the clinic total time budget is fixed to the 
maximum time spent in a week before the criteria change (209 minutes). Clinic capacity is estimated by dividing the 
total time budget by the time spent per patient per week. The top panel shows the changes in the time spent per 
patient per week and the bottom panel translates those changes into changes in estimated clinic capacity. 
 
All rights reserved. No reuse allowed without permission. 
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 





Figure 6: Mean Time in Range by Time Since Diabetes Onset, Comparing Cohorts with 
and without Remote Monitoring 
The mean TIR in the remotely monitored cohort is 65.8% (95% CI: 60.5%, 70.9%) at 12 months since diabetes onset 
versus 57.0% (95% CI: 50.9%, 63.1%) in the cohort without remote monitoring. The 95% CI of the difference in the 
means at 12 months from a two-sample t-test is [0.6%, 16.9%] and the p-value is 0.0357. Note that remote 
monitoring was not assigned randomly so we cannot make a causal claim here. Summary statistics (remote 
monitoring vs no remote monitoring cohort): 27/58 vs 13/25 female, 14/58 vs 0/25 public insurance, 10.1 (SD: 4.7) vs 
9.6 (SD: 5.1) years mean age on May 25, 2020. 
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Estimating the effect of remote review and contacts on glucose management 
 
Regression specification to estimate effect of contacts on TIR: 
 
TI ,   β  βcontac ,  βTI ,      ε , 
 
 , is the proportion (0-1) of time patient i was in range in week t. is the estimated intercept. 
 , is an indicator variable equal to 1 if patient i received a remote contact in week t-1 
and equal to zero otherwise. is the coefficient of interest, representing the estimated effect of 
a remote contact in week t-1 on TIR in week t.   is the patient-level random or fixed effect 
depending on the estimated model. ε , is the residual.  
 
We fit two models using the R plm package, one with patient-level fixed effects and one with 
patient-level random effects.1 Random effects were fit using the default swar method.2 To also 
test a non-linear model, we fit a causal forest to estimate the average effect of remote contact 
on TIR. We used the R grf package to estimate the average treatment effect on the treated.3 
This involved first trained a random forest regression model on the control variable  , to 
estimate the propensity of contact in the previous week  ,. Then, the causal forest 
model predicts individual treatment effects based on the estimated propensities and the control 
 ,. Finally, we estimate the average treatment effect across the treated (i.e. contacted) 
patient-weeks. The hyperparameters of both forest models were tuned using the grf package’s 
built-in automatic tuning capabilities. 
 
The sample used to train the models contained 3,657 patient-weeks and 113 unique patients. 
Only patients that had been tracked for at least twelve weeks were included, and the sample 
was limited to observations with  ,  0.7 to remove patients that already have good 
glucose control when eligible for contact. 525 of the observations had  ,  1. 
 
The estimated effects of contacts on TIR is 1.6pp (SE: 0.7pp) in the linear model with patient 
random effect, 2.3pp (SE: 0.7pp) in the linear model with patient fixed effect, and 1.7pp (SE: 
0.7pp) in the causal forest (Table A1). For the regression models, the estimated coefficients  , 
their standard errors and p-values are reported in Table S1. For the causal forest, the estimated 
average treatment effect on the treated and its standard error is reported. 
 
                                                
1 Croissant Y, Millo G (2008). “Panel Data Econometrics in R: The plm Package.” Journal of Statistical 
Software, 27(2), 1–43. doi: 10.18637/jss.v027.i02. 
2 Swamy and Arora 1972 
3 Wager S, Athey S. Estimation and inference of heterogeneous treatment effects using random forests. 
Journal of the American Statistical Association. 2018 Jul 3;113(523):1228-42. 
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Logistic regression specification to estimate effect of contacts on the odds that patient’s TIR 
increases by 5pp or more: 
 
Logit!I!TI ,  –  TI , # 0.05%%  β  βcontac ,  βTI ,      ε , 
 
The variable definitions are identical to those described in the earlier regression specification. 
I!TI ,  –  TI , # 0.05% is an indicator variable equal to one when the change in TIR of patient 
i increases by 5pp or more from week t-2 to week t. exp!β% is the parameter of interest, which 
estimates the odds ratio (OR) of a TIR improvement of 5pp or more when there is a contact in 
the middle week relative to when there is no contact, controlling for the TIR of the first week. 
The model was fit with same sample as before, and a model was fit separately with patient-level 
random effects and with patient-level fixed effects. The estimated ORs, their 95% confidence 




Table S1: Estimated effects of remote contacts on patients’ time in range (TIR) 
Model 
Estimated Effect of 
Contact on TIR 
Standard 
Error Pr(>|t|) 
Linear regression with patient-level random effects 0.01644 0.00692 0.0176 
Linear regression with patient-level fixed effects 0.02250 0.00676 0.0009 




Table S2: Estimated effects of remote contacts on the odds that TIR improves 
by ≥ 5pp 
Model 
Estimated effect of 
Contact (Odds ratio) 95% CI Pr(>|z|) 
Logistic regression with patient-level random effects 1.292 1.020–1.637 0.0329 
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